

L Number	Hits	Search Text	DB	Time stamp
2	2604	phenylephrine methylaminoethanolphenol mesaton mesatone metaoxedrin mezaton	USPAT; US-PGPUB	2003/02/04 17:22
3	2586	pyrilamine pyranisamine nyscaps pyra anhistabs copsamine coradon dorantamin isamin mepyramine statomin	USPAT; US-PGPUB	2003/02/04 17:23
4	3419	magnesium adj aluminum adj silicate	USPAT; US-PGPUB	2003/02/04 17:24
5	3204	mgal2si208 or (mgal2(sio4)(phenylephrine methylaminoethanolphenol mesaton mesatone metaoxedrin mezaton )) or neuslin or (magnesium adj aluminate adj metasilicate) or (aluminum adj magnesium adj silicate)	USPAT; US-PGPUB	2003/02/04 17:25
6	437	(phenylephrine methylaminoethanolphenol mesaton mesatone metaoxedrin mezaton ) and (pyrilamine pyranisamine nyscaps pyra anhistabs copsamine coradon dorantamin isamin mepyramine statomin )	USPAT; US-PGPUB	2003/02/04 17:25
7	17	((phenylephrine methylaminoethanolphenol mesaton mesatone metaoxedrin mezaton ) and (pyrilamine pyranisamine nyscaps pyra anhistabs copsamine coradon dorantamin isamin mepyramine statomin )) and (magnesium adj aluminum adj silicate) and (mgal2si208 or (mgal2(sio4)(phenylephrine methylaminoethanolphenol mesaton mesatone metaoxedrin mezaton )) or neuslin or (magnesium adj aluminate adj metasilicate) or (aluminum adj magnesium adj silicate) )	USPAT; US-PGPUB	2003/02/04 17:25

FILE 'REGISTRY' ENTERED AT 17:03:18 ON 04 FEB 2003

L1 40 S PHENYLEPHRINE  
L2 14 S PYRILAMINE  
L3 37 S TANNIC ACID OR TANNATE  
L4 7 S MAGNESIUM ALUMINUM SILICATE

FILE 'CAPLUS, USPATFULL, BIOSIS, EMBASE' ENTERED AT 17:11:21 ON 04 FEB 2003

FILE 'CAPLUS' ENTERED AT 17:11:33 ON 04 FEB 2003

S PHENYLEPHRINE OR 154-86-9/REG# OR 61-76-7/REG# OR 59-42-7/

FILE 'REGISTRY' ENTERED AT 17:12:41 ON 04 FEB 2003

L5 1 S 59-42-7/RN

FILE 'CAPLUS' ENTERED AT 17:12:41 ON 04 FEB 2003

L6 5634 S L5

FILE 'REGISTRY' ENTERED AT 17:12:42 ON 04 FEB 2003

L7 1 S 61-76-7/RN

FILE 'CAPLUS' ENTERED AT 17:12:44 ON 04 FEB 2003

L8 865 S L7

FILE 'REGISTRY' ENTERED AT 17:12:44 ON 04 FEB 2003

L9 1 S 154-86-9/RN

FILE 'CAPLUS' ENTERED AT 17:12:45 ON 04 FEB 2003

L10 34 S L9  
L11 12005 S PHENYLEPHRINE OR L10 OR L8 OR L6  
L12 2154 S PYRILAMINE OR 91-84-9/RN OR 59-33-6/RN  
L13 1350 S MAGNESIUM ALUMINUM SILICATE OR 12511-31-8/RN OR 12252-50-5/RN  
L14 6827 S 1401-55-4/RN OR TANNIC ACID OR TANNATE  
L15 130 S L11 AND L12  
L16 0 S L15 AND L13 AND L14  
L17 1 S L15 AND L13  
L18 7 S L15 AND L14  
L19 130 DUP REM L15 (0 DUPLICATES REMOVED)  
L20 7 DUP REM L18 (0 DUPLICATES REMOVED)  
L21 76 S L15 AND (MALEATE OR CITRATE OR CHLORIDE OR BROMIDE OR ACETATE  
L22 76 FOCUS L21 1-

=>

ACCESSION NUMBER: 2002:71812 CAPLUS  
 DOCUMENT NUMBER: 136:123660  
 TITLE: A process for the manufacture of pharmaceutical grade **tannic acid** salts  
 INVENTOR(S): Srinivasan, Chidambaram Venkateswaran; Reddy, Mamilla Srinivas; Khamar, Bakulesh Mafatlal  
 PATENT ASSIGNEE(S): Cadila Pharmaceuticals Limited, India  
 SOURCE: PCT Int. Appl., 10 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005747	A2	20020124	WO 2001-IB1254	20010713
WO 2002005747	A3	20021010		

W: CA, MX, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.: IN 2000-MU661 A 20000714

AB Antihistamines are available in the form of free bases as well as salts i.e. hydrochlorides, maleates, **tannates**, etc. Frequently, it is necessary to utilize antihistamines in the form of **tannate** salts because such salts are generally quite stable and may be administered without any side effects. **Tannic acid**, which is available com., usually contains about 5% water, has a mol. wt. of about 1700 and is typically produced from Turkish or Chinese nut-gall. Antihistamine **tannic acid** salts presently manufd. com., are relatively impure. Such **tannates** are prepd. by the reaction of antihistamine base with **tannic acid** by using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70%) and decompn. products e.g. 2-5% along with a significant amt., IPA (6-10%) remains with the product, which cannot be removed. According to present invention, the **tannates** are made by dissolving **tannic acid** and amine in different compatible solvents. The solvents can be halogenated alkanes or carboxylic esters. Examples of halogenated alkane is CHCl<sub>3</sub> and that of alkanolic ester is EtOAc. This method gives **tannates** which are lighter in color. Thus, ephedrine **tannate** was prepd. by mixing EtOAc 330 mL, ephedrine 10, **tannic acid** 20 g in 230 mL EtOAc and hexane 800 mL. The above **tannate** was quite pure and contained the base 30.44, and **tannic acid** 64.30%.

IT Tannins

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antihistamine salts; manuf. of pharmaceutical grade **tannic acid** salts)

IT Carboxylic acids, uses

RL: NUU (Other use, unclassified); USES (Uses)

(esters; manuf. of pharmaceutical grade **tannic acid** salts)

IT Alkanes, uses

RL: NUU (Other use, unclassified); USES (Uses)

(halo; manuf. of pharmaceutical grade **tannic acid** salts)

IT Antihistamines

(manuf. of pharmaceutical grade **tannic acid** salts)

IT 67-66-3, uses 75-09-2, Methylene chloride, uses 79-20-9, Methyl acetate 107-06-2, Ethylene dichloride, uses 108-21-4, IsoPropyl acetate 109-60-4, Propyl acetate 141-78-6, Ethyl acetate, uses

RL: NUU (Other use, unclassified); USES (Uses)  
 (manuf. of pharmaceutical grade **tannic acid** salts)

IT 77-23-6DP, Carbetapentane, **tannic acid** salts  
 90-82-4DP, PseudoEphedrine, **tannic acid** salts  
 299-42-3DP, Ephedrine, **tannic acid** salts  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (manuf. of pharmaceutical grade **tannic acid** salts)

IT 58-73-1D, Diphenhydramine, **tannic acid** salts  
**59-42-7D, Phenylephrine, tannic acid**  
 salts 82-88-2D, Phenindamine, **tannic acid** salts  
 86-21-5D, Pheniramine, **tannic acid** salts 86-22-6D,  
 Brompheniramine, **tannic acid** salts 91-81-6D,  
 Tripeleennamine, **tannic acid** salts 91-84-9D,  
**Pyrilamine, tannic acid** salts 92-12-6D,  
 Phenyltoloxamine, **tannic acid** salts 118-23-0D,  
 Bromodiphenhydramine, **tannic acid** salts 129-03-3D,  
 Cyproheptadine, **tannic acid** salts 132-22-9D,  
 Chlorpheniramine, **tannic acid** salts 15686-51-8D,  
 Clemastine, **tannic acid** salts  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (manuf. of pharmaceutical grade **tannic acid** salts)

=> d ibib abs it 120 2-7

L20 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:71811 CAPLUS

DOCUMENT NUMBER: 136:123659

TITLE: A process for the manufacture of pharmaceutical grade **tannic acid** salts

INVENTOR(S): Khamar, Bakulesh Mafatlal; Srinivasan, Chidambaram  
 Venkateswaran; Mitra, Jayati

PATENT ASSIGNEE(S): Cadila Pharmaceuticals Limited, India

SOURCE: PCT Int. Appl., 9 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005746	A2	20020124	WO 2001-IB1252	20010713
WO 2002005746	A3	20020502		

W: CA, MX, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, TR

PRIORITY APPLN. INFO.: IN 2000-MJ662 A 20000714

AB Antihistamines are available in the form of free bases as well as salts i.e. hydrochlorides, maleates, **tannates**, etc. Frequently, it is necessary to utilize antihistamines in the form of **tannate** salts because such salts are generally quite stable and may be administered without any side effects. **Tannic acid**, which is available com., usually contains about 5% water, has a mol. wt. of about 1700 and is typically produced from Turkish or Chinese nut-gall. Antihistamine **tannic acid** salts presently manufd. com., are relatively impure. Such **tannates** are prepd. by the reaction of antihistamine base with **tannic acid** by using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70%) and decompn. products e.g. 2-5% along with a significant amt., IPA (6-10%) remains with the product, which cannot be removed.

According to present invention, for specific types of **tannates**, IPA is removed by adding water, while stirring and dispersing the wet cake of **tannate**. It is then filtered and the **tannate** residue is dried to obtain pharmaceutical grade **tannate**. Thus, chlorpheniramine **tannate** was prepd. by mixing IPA 850 mL, chlorpheniramine base 43.3, **tannic acid** 40.7 gms in 450 mL IPA, hexane 100 and water 1000 mL. The above **tannate** was quite pure and contained the base 41.65, and **tannic acid** 54.20%.

IT Tannins

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antihistamine salts; manuf. of pharmaceutical grade **tannic acid** salts)

IT 67-63-0, Isopropanol, uses 110-54-3, Hexane, uses

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PROC (Process); USES (Uses)

(manuf. of pharmaceutical grade **tannic acid** salts)

IT 91-84-9DP, **Pyrilamine, tannic acid** salts

132-22-9DP, Chlorpheniramine, **tannic acid** salts

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(manuf. of pharmaceutical grade **tannic acid** salts)

IT 58-73-1D, Diphenhydramine, **tannic acid** salts

**59-42-7D, Phenylephrine, tannic acid**

salts 77-23-6D, Carbetapentane, **tannic acid** salts

82-88-2D, Phenindamine, **tannic acid** salts 86-21-5D,

Pheniramine, **tannic acid** salts 86-22-6D,

Brompheniramine, **tannic acid** salts 90-82-4D,

PseudoEphedrine, **tannic acid** salts 91-81-6D,

Tripelennamine, **tannic acid** salts 92-12-6D,

Phenyltoxamine, **tannic acid** salts 118-23-0D,

Bromodiphenhydramine, **tannic acid** salts 129-03-3D,

Cyproheptadine, **tannic acid** salts 299-42-3D,

Ephedrine, **tannic acid** salts 15686-51-8D,

Clemastine, **tannic acid** salts

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(manuf. of pharmaceutical grade **tannic acid** salts)

L20 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:71810 CAPLUS

DOCUMENT NUMBER: 136:123658

TITLE: A process for the manufacture of pharmaceutical grade **tannic acid** salts

INVENTOR(S): Khamar, Bakulesh Mafatlal; Srinivasan, Chidambaram Venkateswaran; Muralidhar, Kompaly; Mitra, Jyati; Reddy, Mamilla Srinivas; Somannawar, Yallappa Somanna

PATENT ASSIGNEE(S): Cadila Pharmaceuticals Limited, India

SOURCE: PCT Int. Appl., 9 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005745	A2	20020124	WO 2001-IB1250	20010713
WO 2002005745	A3	20021010		

W: CA, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.:

IN 2000-MU660

A 20000714

AB Antihistamines are available in the form of free bases as well as salts i.e. hydrochlorides, maleates, **tannates**, etc. Frequently, it is necessary to utilize antihistamines in the form of **tannate** salts because such salts are generally quite stable and may be administered without any side effects. **Tannic acid**, which is available com., usually contains about 5% water, has a mol. wt. of about 1700 and is typically produced from Turkish or Chinese nut-gall. Antihistamine **tannic acid** salts presently manufd. com., are relatively impure. Such **tannates** are prepd. by the reaction of antihistamine base with **tannic acid** by using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70%) and decompn. products e.g. 2-5% along with a significant amt., IPA (6-10%) remains with the product, which cannot be removed. According to present invention, IPA is removed by using a solvent for IPA which is highly volatile, which does not dissolve **tannates** but disperses the wet cake of the **tannate**. The solvent, hexane, is added to the wet cake, while stirring and the cake is filtered. This results in a residue of **tannates** with a lower IPA content. Thus, **phenylephrine tannate** was prepd. by mixing IPA 1200 mL, **phenylephrine** base 20, **tannic acid** 39.4 g in 400 mL IPA, hexane 1000 mL.

IT Tannins

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(antihistamine salts; manuf. of pharmaceutical grade **tannic acid** salts)

IT 67-63-0, Isopropanol, uses 110-54-3, Hexane, uses

RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PROC (Process); USES (Uses)  
(manuf. of pharmaceutical grade **tannic acid** salts)

IT 59-42-7DP, **Phenylephrine, tannic acid**

salts 132-22-9DP, Chlorpheniramine, **tannic acid** salts

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(manuf. of pharmaceutical grade **tannic acid** salts)

IT 58-73-1D, Diphenhydramine, **tannic acid** salts

77-23-6D, Carbetapentane, **tannic acid** salts

82-88-2D, Phenindamine, **tannic acid** salts 86-21-5D,

Pheniramine, **tannic acid** salts 86-22-6D,

Brompheniramine, **tannic acid** salts 90-82-4D,

Pseudoephedrine, **tannic acid** salts 91-81-6D,

Tripeleminamine, **tannic acid** salts 91-84-9D,

**Pyrilamine, tannic acid** salts 92-12-6D,

Phenyltoloxamine, **tannic acid** salts 118-23-0D,

Bromodiphenhydramine, **tannic acid** salts 129-03-3D,

Cyproheptadine, **tannic acid** salts 299-42-3D,

Ephedrine, **tannic acid** salts 15686-51-8D,

Clemastine, **tannic acid** salts

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(manuf. of pharmaceutical grade **tannic acid** salts)

L20 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:516680 CAPLUS

DOCUMENT NUMBER: 137:83654

TITLE: Antitussive/antihistaminic/decongestant compositions containing **tannates** of carbetapentane, **pyrilamine** and **phenylephrine**

INVENTOR(S): Leflein, Ronald; D'addio, Alexander D.

PATENT ASSIGNEE(S): Medpointe Healthcare Inc., USA

SOURCE: U.S., 3 pp.

CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6417206	B1	20020709	US 2001-771130	20010126
PRIORITY APPLN. INFO.:			US 2001-771130	20010126

AB **Tannate** compns. are disclosed consisting essentially of carbetapentane **tannate**, **pyrilamine tannate** and **phenylephrine tannate** are effective when administered orally for the symptomatic relief of cough assocd. with respiratory tract conditions such as the common cold, bronchial asthma, and acute and chronic bronchitis. For example, tablets contained carbetapentane **tannate** 60 mg, **pyrilamine tannate** 40 mg, and **phenylephrine tannate** 10 mg, and oral suspension contained (per 5 mL) carbetapentane **tannate** 30 mg, **pyrilamine tannate** 30 mg, and **phenylephrine tannate** 5 mg.

IT Respiratory tract  
(disease; oral antitussive-antihistaminic-decongestant compns. contg. carbetapentane, **phenylephrine**, and **pyrilamine as tannates**)

IT Antihistamines  
Antitussives  
Cough  
Decongestants  
(oral antitussive-antihistaminic-decongestant compns. contg. carbetapentane, **phenylephrine**, and **pyrilamine as tannates**)

IT Tannins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oral antitussive-antihistaminic-decongestant compns. contg. carbetapentane, **phenylephrine**, and **pyrilamine as tannates**)

IT Drug delivery systems  
(suspensions, oral; oral antitussive-antihistaminic-decongestant compns. contg. carbetapentane, **phenylephrine**, and **pyrilamine as tannates**)

IT Drug delivery systems  
(tablets; oral antitussive-antihistaminic-decongestant compns. contg. carbetapentane, **phenylephrine**, and **pyrilamine as tannates**)

IT 59-33-6D, **Pyrilamine, tannates** 59-42-7D, **Phenylephrine, tannates** 77-23-6D, Carbetapentane, **tannates**  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(oral antitussive-antihistaminic-decongestant compns. contg. carbetapentane, **phenylephrine**, and **pyrilamine as tannates**)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2001:666683 CAPLUS  
DOCUMENT NUMBER: 135:231697  
TITLE: Antihistaminic/decongestant compositions  
INVENTOR(S): Gordziel, Steven A.  
PATENT ASSIGNEE(S): Carter-Wallace, Inc., USA

SOURCE: U.S., 3 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6287597	B1	20010911	US 1999-267826	19990312
PRIORITY APPLN. INFO.:			US 1999-267826	19990312

AB **Tannate** compns. consisting essentially of **pyrilamine tannate** and **phenylephrine tannate** which are effective when administered orally for the symptomatic relief of coryza assocd. with the common cold, sinusitis, allergic rhinitis and upper respiratory tract conditions are disclosed. A tablet contained **pyrilamine tannate** 60.0, **phenylephrine tannate** 25.01, starch 94.0, methylcellulose 150, polygalactouronic acid 32.0, dibasic calcium phosphate dihydrate 97.0, talc 5.8, and magnesium stearate mg.

IT Nose  
(allergic rhinitis; antihistaminic/decongestant compns.)

IT Antihistamines  
Common cold  
Decongestants  
(antihistaminic/decongestant compns.)

IT Nose  
(coryza; antihistaminic/decongestant compns.)

IT Drug delivery systems  
(oral; antihistaminic/decongestant compns.)

IT Tannins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(**phenylephrine** and **pyrilamine** salts;  
antihistaminic/decongestant compns.)

IT Respiratory tract  
(sinusitis; antihistaminic/decongestant compns.)

IT Drug delivery systems  
(suspensions, oral; antihistaminic/decongestant compns.)

IT Drug delivery systems  
(tablets; antihistaminic/decongestant compns.)

IT Respiratory tract  
(upper, infection; antihistaminic/decongestant compns.)

IT **59-42-7D, Phenylephrine, tannate** salts  
91-84-9D, **Pyrilamine, tannate** salts  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antihistaminic/decongestant compns.)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:599327 CAPLUS

DOCUMENT NUMBER: 127:262512

TITLE: Preparation of antihistamine **tannates**.

INVENTOR(S): Chopdekar, Vilas M.; Schleck, James R.; Brown, Vernon  
A.; Guo, Cheng

PATENT ASSIGNEE(S): Jame Fine Chemicals, Inc., USA

SOURCE: U.S., 4 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5663415	A	19970902	US 1996-671604	19960628
PRIORITY APPLN. INFO.:			US 1996-671604	19960628
AB	An antihistamine free base is contacted with <b>tannic acid</b> in the presence of H <sub>2</sub> O for 5 min to 4 h at a max. temp. such that .ltoreq.5 wt. % of the antihistamine <b>tannate</b> will be decompd. followed by freeze drying to remove .gtoreq.90% of the H <sub>2</sub> O at a temp. and pressure such that decompn. is limited to .ltoreq.5%. Thus, <b>phenylephrine</b> was added over 15 min. to <b>tannic acid</b> in H <sub>2</sub> O at 22.degree. followed by stirring for 2 h. The mixt. was then freeze-dried at 200-100 mtorr ant -50.degree. to -40.degree. for 36 h to give 96% <b>phenylephrine tannate</b> contg. 2 wt.% H <sub>2</sub> O.			
IT	Tannins RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (compds. with (R)-3-hydroxy-.alpha.-[(methylamino)methyl]benzenemethanol; prepn. of antihistamine <b>tannates</b> )			
IT	Tannins RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. of antihistamine <b>tannates</b> )			
IT	<b>59-42-7DP, Phenylephrine</b> , reaction products with <b>tannic acid</b> RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (prepn. of antihistamine <b>tannates</b> )			
IT	58-73-1, Diphenhydramine <b>59-33-6 59-42-7, Phenylephrine</b> 77-23-6, Carbetapentane 86-21-5, Pheniramine 86-22-6, Brompheniramine 90-82-4, Pseudoephedrine 91-81-6, Tripeleminamine 92-12-6, Phenyltoloxamine 113-92-8 118-23-0, Bromodiphenhydramine 129-03-3, Cyproheptadine 299-42-3, Ephedrine 569-59-5 15686-51-8, Clemastine RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. of antihistamine <b>tannates</b> )			

L20 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:520800 CAPLUS

DOCUMENT NUMBER: 113:120800

TITLE: Skin penetration enhancers for salts of amine-functional drugs

INVENTOR(S): Manring, Gary Lee; Smith, Ronald Lee

PATENT ASSIGNEE(S): Procter and Gamble Co., USA

SOURCE: Eur. Pat. Appl., 15 pp.  
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 351897	A2	19900124	EP 1989-201447	19890606
EP 351897	A3	19900321		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8936511	A1	19891221	AU 1989-36511	19890616
DK 8902983	A	19900202	DK 1989-2983	19890616
ZA 8904588	A	19900328	ZA 1989-4588	19890616
JP 02209815	A2	19900821	JP 1989-155565	19890617
PRIORITY APPLN. INFO.:			US 1988-208197	19880617
AB	The transdermal penetration of amine-functional drug addn. salts (other			

than opioid analgesics) is enhanced by C7-22 fatty acids (m.p. <50.degree.) used together with C3-4 alkanediols. The in vitro transdermal penetration of pseudoephedrine-HCl through the human skin was enhanced by a 5:95 mixt. of 1,2-propanediol and oleic acid.

- IT Adrenergic agonists
- Anesthetics
- Antiarrhythmics
- Antiemetics
- Antihistaminics
- Antihypertensives
- Antitussives
- Bronchodilators
- Cholinergic antagonists
  - (amine-functional, addn. salts of, skin penetration enhancers for, fatty acid mixts. with alkanediols as)
- IT Pruritus
  - (treatment of, amine addn. salts for, skin penetration enhancers for, fatty acid mixts. with alkanediols as)
- IT Glycols, biological studies
  - RL: BIOL (Biological study)
  - (C3-4, as skin penetration enhancers, for addn. salts of amine-functional drugs)
- IT Fatty acids, biological studies
  - RL: BIOL (Biological study)
  - (C7-22, as skin penetration enhancers, for addn. salts of amine-functional drugs)
- IT Amines, compounds
  - RL: BIOL (Biological study)
  - (salts, skin penetration enhancers for, fatty acid mixts. with alkanediols as)
- IT Pharmaceutical dosage forms
  - (transdermal, skin penetration enhancers in, fatty acid mixts. with alkanediols as)
- IT 57-55-6, 1,2-Propanediol, biological studies 112-80-1, 9-Octadecenoic acid (Z)-, biological studies 143-07-7, Dodecanoic acid, biological studies 584-03-2, 1,2-Butanediol
  - RL: BIOL (Biological study)
  - (as skin penetration enhancer, for addn. salts of amine-functional drugs)
- IT 50-54-4, Quinidine sulfate 50-96-4, Isoetharine hydrochloride 50-98-6, Ephedrine hydrochloride 51-56-9, Homatropine hydrobromide 52-28-8, Codeine phosphate 55-16-3, Scopolamine hydrochloride 55-48-1, Atropine sulfate 58-33-3, Promethazine hydrochloride 59-33-6, **Pyrilamine maleate 59-42-7D, tannates** 61-12-1, Dibucaine hydrochloride 61-76-7, **Phenylephrine** hydrochloride 69-09-0, Chlorpromazine hydrochloride 73-78-9, Lidocaine hydrochloride 91-84-9D, **tannates** 113-92-8, Chlorpheniramine maleate 114-49-8, Scopolamine hydrobromide 125-69-9, Dextromethorphan hydrobromide 132-22-9D, **tannates** 134-72-5, Ephedrine sulfate 136-47-0, Tetracaine hydrochloride 147-24-0, Diphenhydramine hydrochloride 154-41-6, Phenylpropanolamine hydrochloride 154-69-8, Tripeleminamine hydrochloride 299-42-3D, **tannates** 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 306-21-8, Hydroxyamphetamine hydrobromide 318-98-9 345-78-8, Pseudoephedrine hydrochloride 532-76-3, Hexylcaine hydrochloride 536-43-6, Dyclonine hydrochloride 550-70-9, Triprolidine hydrochloride 562-10-7 569-59-5, Phenindamine tartrate 614-39-1, Procainamide hydrochloride 637-21-8, Homatropine hydrochloride 876-26-6, Hydroxyamphetamine hydrochloride 969-33-5, Cyproheptadine hydrochloride 980-71-2, Brompheniramine maleate 1212-72-2, Mephentermine sulphate 1722-62-9, Mepivacaine hydrochloride 2438-32-6, Dexchlorpheniramine maleate 3505-38-2, Carbinoxamine maleate 3858-89-7, Chlorprocaine hydrochloride

3978-86-7, Azatadine maleate 4205-91-8, Clonidine hydrochloride  
5874-97-5, Metaproterenol sulfate 6033-93-8, Carbinoxamine hydrochloride  
6036-95-9, **Pyrilamine** hydrochloride 6059-45-6 6138-56-3,  
Tripeleennamine citrate 6533-43-3 7054-25-3, Quinidine gluconate  
7104-40-7, Metaproterenol hydrochloride 7460-12-0, Pseudoephedrine  
sulfate 14362-31-3, Chlorcyclizine hydrochloride 14976-57-9,  
Clemastine fumarate 16639-82-0 17162-39-9 18010-40-7, Bupivacaine  
hydrochloride 23031-32-5, Terbutaline sulfate 23142-01-0,  
Carbetapentane citrate 36236-67-6, Meclizine hydrochloride 36637-19-1,  
Etidocaine hydrochloride 41670-27-3 51022-70-9, Albuterol sulfate  
51366-19-9, Triprolidine oxalate 76095-16-4, Enalapril maleate  
85405-59-0D, 3S-Hydroxy-10,11-dihydroquinidine, addn. salts 85405-60-3D,  
3R-Hydroxy-10,11-dihydroquinidine, addn. salts 88637-37-0 109513-81-7,  
Codeine N-oxide hydrochloride 129225-27-0D, 3(R)-Hydroxy-O-acetyl-10,11-  
dihydroquinidine, addn. salts 129263-46-3D, 3(S)-Hydroxy-O-acetyl-10,11-  
dihydroquinidine, addn. salts

RL: BIOL (Biological study)

(skin penetration of, enhancement of, by fatty acid mixts. with  
alkanediols)

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:483926 CAPLUS

DOCUMENT NUMBER: 107:83926

TITLE: **Magnesium aluminum silicate**-wax as medicament adsorbates

INVENTOR(S): Mozda, Ronald F.

PATENT ASSIGNEE(S): Warner-Lambert Co., USA

SOURCE: Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 219458	A2	19870422	EP 1986-810428	19860929
EP 219458	A3	19880120		
EP 219458	B1	19900523		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
US 4753800	A	19880628	US 1985-784280	19851004
AU 8663456	A1	19870409	AU 1986-63456	19861001
AU 565750	B2	19870924		
JP 62116507	A2	19870528	JP 1986-234741	19861003
JP 02020604	B4	19900510		
CA 1276885	A1	19901127	CA 1986-519723	19861003

PRIORITY APPLN. INFO.: US 1985-784280 19851004

AB Medications are dissolved or dispersed in molten edible wax, and sorbed into Mg Al silicate. This process masks the taste of the medication more effectively than simple adsorption into Mg Al silicate. Guaifenesin 160 g was added to molten carnauba wax 310 g, and Mg Al silicate 530 g was mixed in. After cooling, the solid was milled to give free flowing particles of .apprx.100 .mu.m. This compn. had a good taste, whereas 16% guaifenesin in carnauba wax or in Mg Al silicate both had a bitter taste.

**Pyrilamine** maleate adsorbate(25 mg drug/tablet) 250.0 mg was mixed with cellulose 34.0, lactose 136.8, cellulose gum 2.0, fumed silica 0.7, stearic acid 0.5, and Mg stearate 1.0 mg/tablet.

IT Bitterness  
Taste

(masking of, in drugs, adsorbates for)

IT Chewing gum  
(medicated, wax and **magnesium aluminum silicate** in, as adsorbate)

IT Adsorbed substances  
(of drugs, for masking bitterness, wax and **magnesium aluminum silicate** in)

IT Beeswax  
Carnauba wax  
Candelilla wax  
Esters, biological studies  
Paraffin waxes and Hydrocarbon waxes, biological studies  
Waxes and Waxy substances  
RL: BIOL (Biological study)  
(pharmaceutical adsorbates contg., in combination with aluminum magnesium silicate)

IT Analgesics  
Antihistaminics  
Antitussives  
Decongestants  
Expectorants  
(taste masking adsorbate-contg. formulation of)

IT Anticholesteremics and Hypolipemics  
 Appetite depressants  
 Cathartics  
 Inflammation inhibitors  
 Alkaloids, biological studies  
 Vitamins  
 RL: BIOL (Biological study)  
 (taste masking adsorbate-contg. pharmaceutical formulation of)

IT Bronchodilators  
 (antiasthmatics, taste masking adsorbate-contg. formulation of)

IT Castor oil  
 RL: BIOL (Biological study)  
 (hydrogenated, pharmaceutical adsorbates contg., in combination with  
 aluminum magnesium silicate)

IT Pharmaceutical dosage forms  
 (lozenges, adsorbates in, for masking bitterness, wax and  
**magnesium aluminum silicate** in)

IT Pharmaceutical dosage forms  
 (tablets, adsorbates in, for masking bitterness, wax and  
**magnesium aluminum silicate** in)

IT Pharmaceutical dosage forms  
 (tablets, chewable, adsorbates in, for masking bitterness, wax and  
**magnesium aluminum silicate** in)

IT 57-11-4, Stearic acid, biological studies 112-92-5, Stearyl alcohol  
 36653-82-4, Cetyl alcohol  
 RL: BIOL (Biological study)  
 (pharmaceutical adsorbates contg., in combination with aluminum  
 magnesium silicate)

IT **1327-43-1, Magnesium aluminum silicate**  
 RL: BIOL (Biological study)  
 (pharmaceutical adsorbates, in combination with wax)

IT 52-28-8, Codeine phosphate 54-11-5, Nicotine 58-08-2, Caffeine,  
 biological studies 58-55-9, Theophylline, biological studies  
**59-33-6, Pyrilamine** maleate 60-87-7, Promethazine  
**61-76-7, Phenylephrine** hydrochloride 65-45-2,  
 Salicylamide 77-09-8, Phenolphthalein 93-14-1, Guaifenesin 103-90-2,  
 Acetaminophen 113-92-8, Chlorpheniramine maleate 117-10-2, Danthron  
 125-69-9 125-71-3 128-62-1, Noscapine 147-24-0, Diphenhydramine  
 hydrochloride 299-42-3 345-78-8, Pseudoephedrine hydrochloride  
 486-12-4, Triprolidine 511-13-7, Chlophedianol hydrochloride 523-87-5,  
 Dimenhydrinate 562-10-7 569-59-5, Phenindamine tartrate 569-65-3,  
 Meclizine 586-06-1, Metaproterenol 603-50-9 644-62-2, Meclophenamic  
 acid 1176-08-5, Phenyltoloxamine citrate 1420-53-7, Codeine sulfate  
 4345-16-8, Phenylpropanolamine hydrochloride 15687-27-1, Ibuprofen  
 23142-01-0, Carbetapentane citrate 25812-30-0, Gemfibrozil 34552-84-6  
 57-27-2P, Morphine, preparation  
 RL: BIOL (Biological study)  
 (taste masking adsorbate-contg. formulation of)

22 ANSWER 1 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1980:625705 CAPLUS  
 DOCUMENT NUMBER: 93:225705  
 TITLE: Simultaneous GLC analysis of salicylamide, phenylpropanolamine hydrochloride, caffeine, chlorpheniramine **maleate**, **phenylephrine** hydrochloride, and **pyrilamine maleate** in capsule preparations  
 AUTHOR(S): De Fabrizio, Fabrizio  
 CORPORATE SOURCE: Adcock-Ingram Lab., Johannesburg, 2000, S. Afr.  
 SOURCE: Journal of Pharmaceutical Sciences (1980), 69(7), 854-5  
 CODEN: JPMSAE; ISSN: 0022-3549  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB A gas-liq. chromatog. method is described for the quant. detn. of salicylamide [65-45-2], phenylpropanolamine-HCl [154-41-6], caffeine [58-08-2], chlorpheniramine **maleate** [113-92-8], **phenylephrine**-HCl [61-76-7], and **pyrilamine maleate** [59-33-6]. The sample was dissolved in EtOH, and an aliquot of the soln. was brought to dryness and treated with 0.1 mL of 4-(dimethylamino)pyridine in pyridine-Ac2O (1:1). The components were isolated and measured by applying 1 .mu.L of the reaction mixt. to a chromatograph equipped with a flame-ionization detector and fitted with 8% OV-101 glass columns. The accuracy was good. Dicyclohexylphthalate was used as the internal std.

L22 ANSWER 2 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1968:107919 CAPLUS  
 DOCUMENT NUMBER: 68:107919  
 TITLE: Spectrophotometric determination of acetaminophen, **phenylephrine** hydrochloride, codeine phosphate, and **pyrilamine maleate** in tablets or powder  
 AUTHOR(S): De Fabrizio, Fabrizio  
 CORPORATE SOURCE: Propan. Pharm. Ltd., Germiston, S. Afr.  
 SOURCE: Journal of Pharmaceutical Sciences (1968), 57(4), 644-5  
 CODEN: JPMSAE; ISSN: 0022-3549  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB An uv spectrophotometric method was developed for the detn. of acetaminophen, **phenylephrine** hydrochloride, codeine phosphate, and **pyrilamine maleate** after a partial sepn. of them by means of column chromatog. using alginic acid; codeine phosphate and **phenylephrine** hydrochloride are both eluted with 0.01N HCl and detd. simultaneously while acetaminophen and **pyrilamine maleate** are detd. sep.

L22 ANSWER 3 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:182566 CAPLUS  
 DOCUMENT NUMBER: 106:182566  
 TITLE: DSC screening for drug-drug interactions in polypharmaceuticals intended for the alleviation of the symptoms of colds and flu. II  
 AUTHOR(S): Botha, S. A.; Lotter, A. P.; Du Preez, J. L.  
 CORPORATE SOURCE: Chem. Res. Inst. Ind. Pharm., Potchefstroom Univ. CHE, Potchefstroom, 2520, S. Afr.  
 SOURCE: Drug Development and Industrial Pharmacy (1987), 13(2), 345-54  
 CODEN: DDIPD8; ISSN: 0363-9045

DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB DSC screening for drug-drug interactions of a polypharmaceutical capsule dosage form contg. salicylamide [65-45-2], ascorbic acid [50-81-7], **pyrilamine maleate** [59-33-6] and **phenylephrine-HCl** [61-76-7] was performed. All drugs were incompatible with each other.

L22 ANSWER 4 OF 76 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1966:446778 CAPLUS  
 DOCUMENT NUMBER: 65:46778  
 ORIGINAL REFERENCE NO.: 65:8673e-f  
 TITLE: Chromatographic separation and spectrophotometric determination of **phenylephrine** hydrochloride, codeine phosphate, and some other pharmaceuticals in a mixture  
 AUTHOR(S): Smith, Donald J.  
 CORPORATE SOURCE: Food & Drug Admin., San Francisco, CA  
 SOURCE: J. Assoc. Offic. Anal. Chemists (1966), 49(3), 536-41  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Codeine phosphate, chlorpheniramine **maleate**, **pyrilamine maleate**, phenylpropanolamine-HCl, and hydrocortisone **acetate** were analyzed in samples contg. **phenylephrine** -HCl. A series of 4 Celite columns was used to sep. the various pharmaceutical components prior to spectrophotometric analysis. Assays of com. samples were 87.2-118% of declared contents.

L22 ANSWER 5 OF 76 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:875749 CAPLUS  
 DOCUMENT NUMBER: 134:33001  
 TITLE: Alkali metal and alkaline-earth metal **salts** of acetaminophen  
 INVENTOR(S): Ohannesian, Lena A.; Nadig, David; Higgins, John D., III; Rey, Max; Martellucci, Stephen A.  
 PATENT ASSIGNEE(S): McNeill-PPC, Inc., USA  
 SOURCE: U.S., 10 pp., Cont.-in-part of U.S. Ser. No. 987,210, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6160020	A	20001212	US 1998-100284	19980619
WO 9966919	A1	19991229	WO 1999-US13064	19990609
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9943380	A1	20000110	AU 1999-43380	19990609
PRIORITY APPLN. INFO.:			US 1996-771176	B2 19961220
			US 1997-987210	B2 19971209
			US 1998-100284	A 19980619
			WO 1999-US13064	W 19990609
AB Isolated <b>salts</b> of acetaminophen are disclosed. Alkali metal and				

alk.-earth metal **salts** of acetaminophen are formed by reacting the free acid of acetaminophen with the corresponding metal hydroxide and then immediately isolating the resulting **salt**. These **salts** have been found to be more water sol. and less bitter in taste than the free acid form of acetaminophen. The isolated **salts** may also be combined with other active ingredients. A tablet contained calcium acetaminophen 368.23, chlorpheniramine **maleate** 2, microcryst. cellulose 520.77, silica 4.5, and Mg stearate 4.5 mg.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:819235 CAPLUS

DOCUMENT NUMBER: 132:54898

TITLE: Pharmaceutical composition containing a **salt** of acetaminophen and at least one other active ingredient

INVENTOR(S): Ohannesian, Lena A.; Nadig, David; Higgins, John D., III; Rey, Max; Martellucci, Stephen A.

PATENT ASSIGNEE(S): Mcneil-PPC, Inc., USA

SOURCE: PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9966919	A1	19991229	WO 1999-US13064	19990609
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6160020	A	20001212	US 1998-100284	19980619
AU 9943380	A1	20000110	AU 1999-43380	19990609
PRIORITY APPLN. INFO.:			US 1998-100284	A 19980619
			US 1996-771176	B2 19961220
			US 1997-987210	B2 19971209
			WO 1999-US13064	W 19990609

AB This invention relates to pharmaceutical compns. comprising an alkali or alk.-earth metal **salt** of acetaminophen and at least one other active ingredient selected from the group consisting of analgesics, decongestants, expectorants, antitussives, antihistamines, gastrointestinal agents, diuretics, bronchodilators and mixts. thereof. The acetaminophen **salts** have both improved aq. soly. and a less bitter taste than the free acid form of acetaminophen. A tablet contained acetaminophen calcium **salt** 368.23, chlorpheniramine **maleate** 2, microcryst. cellulose 520.77, Cab-O-Sil M5 4.5, and Mg stearate 4.5 mg.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1974:454493 CAPLUS

DOCUMENT NUMBER: 81:54493

TITLE: Collaborative study of an ion exchange method for the



chromatographic separation of mixtures containing expectorants, sympathomimetic amines, antihistamines, or phenothiazine in pharmaceuticals

AUTHOR(S): Smith, Donald J.  
CORPORATE SOURCE: Food Drug Adm., San Francisco, CA, USA  
SOURCE: Journal - Association of Official Analytical Chemists (1974), 57(3), 741-6  
CODEN: JANCA2; ISSN: 0004-5756

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB An ion exchange chromatog. method was applied to the detn. of 9 drugs in various dosage forms, alone or in combination: chlorpheniramine **maleate**, codeine phosphate, dextromethorphan-HBr, glyceryl guaiacolate, **phenylephrine**-HCl, phenylpropanolamine-HCl, K guaiacolsulfonate, promethazine-HCl, and **pyrilamine maleate**. Nitrogenous bases were sepd. from the excipients by retention on a sulfonated polystyrene resin column. These basic compds. were eluted from the column with the appropriate concn. of HCl and were detd. by uv absorption. The org. acids were retained on the quaternary ammonium anion resin. The acidic compds. were eluted from the columns with the appropriate concn. of HCl and detd. by uv absorption. Av. recoveries and std. deviations for the 9 drug ingredients in 3 simulated combinations ranged from a low of 93.2  $\pm$  4.03% (phenylpropanolamine-HCl) to a high of 98.8  $\pm$  4.8% (codeine phosphate), for 6 unknown samples/collaborator. Comparable values were reported for 2 com. sirups collaboratively studied. The method has been adopted as official 1st action for the following compds.: (a) promethazine-HCl, **phenylephrine**-HCl, or phenylpropanolamine-HCl (except in tablets or powders), and K guaiacolsulfonate; (b) promethazine-HCl codeine phosphate, and K guaiacolsulfonate; (c) **phenylephrine**-HCl or phenylpropanolamine-HCl (except in tablets or powders), dextromethorphan-HBr (except in sirups), K guaiacolsulfonate, and **pyrilamine maleate**; and (d) **phenylephrine**-HCl or phenylpropanolamine-HCl (except in tablets or powders), dextromethorphan-HBr (except in sirups), glyceryl guaiacolate, and **pyrilamine maleate**.

L22 ANSWER 8 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1983:410957 CAPLUS  
DOCUMENT NUMBER: 99:10957  
TITLE: Determination of benzalkonium **chloride** in the presence of interfering alkaloids and polymeric substrates by reverse-phase high-performance liquid chromatography

AUTHOR(S): Marsh, Dennis F.; Takahashi, Lloyd T.  
CORPORATE SOURCE: Allergan Pharm., Inc., Irvine, CA, 92713, USA  
SOURCE: Journal of Pharmaceutical Sciences (1983), 72(5), 521-5  
CODEN: JPMSAE; ISSN: 0022-3549

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A specific assay for benzalkonium **chlorides** in the presence of interfering substances, e.g., poly(vinyl alc.) [9002-89-5], in ophthalmic formulations, involved complexing with methyl orange, extg. the complex into 1,2-dichloroethane, and chromatographing on a column of  $\mu$ -Bondapak CN with a mobile phase of pH 5.35 MeCN-0.161M Na propionate (58:42), with detection at 254 nm. Since the method seps. homologs of benzalkonium **chlorides**, the C10 and C18 homologs not present in the ophthalmic system were prepd. and added as internal stds. to improve recovery and precision in the method.

L22 ANSWER 9 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:666683 CAPLUS  
 DOCUMENT NUMBER: 135:231697  
 TITLE: Antihistaminic/decongestant compositions  
 INVENTOR(S): Gordziel, Steven A.  
 PATENT ASSIGNEE(S): Carter-Wallace, Inc., USA  
 SOURCE: U.S., 3 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6287597	B1	20010911	US 1999-267826	19990312
PRIORITY APPLN. INFO.:			US 1999-267826	19990312

AB Tannate compns. consisting essentially of **pyrilamine** tannate and **phenylephrine** tannate which are effective when administered orally for the symptomatic relief of coryza assocd. with the common cold, sinusitis, allergic rhinitis and upper respiratory tract conditions are disclosed. A tablet contained **pyrilamine** tannate 60.0, **phenylephrine** tannate 25.01, starch 94.0, methylcellulose 150, polygalactouronic acid 32.0, dibasic calcium phosphate dihydrate 97.0, talc 5.8, and magnesium stearate mg.  
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 10 OF 76 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:71810 CAPLUS  
 DOCUMENT NUMBER: 136:123658  
 TITLE: A process for the manufacture of pharmaceutical grade tannic acid **salts**  
 INVENTOR(S): Khamar, Bakulesh Mafatlal; Srinivasan, Chidambaram Venkateswaran; Muralidnar, Kompaly; Mitra, Jyati; Reddy, Mamilla Srinivas; Somannawar, Yallappa Somanna  
 PATENT ASSIGNEE(S): Cadila Pharmaceuticals Limited, India  
 SOURCE: PCT Int. Appl., 9 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005745	A2	20020124	WO 2001-IB1250	20010713
WO 2002005745	A3	20021010		

W: CA, US  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR  
 PRIORITY APPLN. INFO.: IN 2000-MU660 A 20000714  
 AB Antihistamines are available in the form of free bases as well as **salts** i.e. hydrochlorides, **maleates**, tannates, etc. Frequently, it is necessary to utilize antihistamines in the form of tannate **salts** because such **salts** are generally quite stable and may be administered without any side effects. Tannic acid, which is available com., usually contains about 5% water, has a mol. wt. of about 1700 and is typically produced from Turkish or Chinese nut-gall. Antihistamine tannic acid **salts** presently manufd. com., are relatively impure. Such tannates are prepd. by the reaction of antihistamine base with tannic acid by using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70%) and decompn.

products e.g. 2-5% along with a significant amt., IPA (6-10%) remains with the product, which cannot be removed. According to present invention, IPA is removed by using a solvent for IPA which is highly volatile, which does not dissolve tannates but disperses the wet cake of the tannate. The solvent, hexane, is added to the wet cake, while stirring and the cake is filtered. This results in a residue of tannates with a lower IPA content. Thus, **phenylephrine** tannate was prepd. by mixing IPA 1200 mL, **phenylephrine** base 20, tannic acid 39.4 g in 400 mL IPA, hexane 1000 mL.

L22 ANSWER 11 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:71812 CAPLUS

DOCUMENT NUMBER: 136:123660

TITLE: A process for the manufacture of pharmaceutical grade tannic acid **salts**

INVENTOR(S): Srinivasan, Chidambaram Venkateswaran; Reddy, Mamilla Srinivas; Khamar, Bakulesh Mafatlal

PATENT ASSIGNEE(S): Cadila Pharmaceuticals Limited, India

SOURCE: PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005747	A2	20020124	WO 2001-IB1254	20010713
WO 2002005747	A3	20021010		

W: CA, MX, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.: IN 2000-MU661 A 20000714

AB Antihistamines are available in the form of free bases as well as

**salts** i.e. hydrochlorides, **maleates**, tannates, etc.

Frequently, it is necessary to utilize antihistamines in the form of tannate **salts** because such **salts** are generally quite stable and may be administered without any side effects. Tannic acid, which is available com., usually contains about 5% water, has a mol. wt. of about 1700 and is typically produced from Turkish or Chinese nut-gall. Antihistamine tannic acid **salts** presently manufd. com., are relatively impure. Such tannates are prepd. by the reaction of antihistamine base with tannic acid by using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70%) and decompn. products e.g. 2-5% along with a significant amt., IPA (6-10%) remains with the product, which cannot be removed. According to present invention, the tannates are made by dissolving tannic acid and amine in different compatible solvents. The solvents can be halogenated alkanes or carboxylic esters. Examples of halogenated alkane is CHCl<sub>3</sub> and that of alkanolic ester is EtOAc. This method gives tannates which are lighter in color. Thus, ephedrine tannate was prepd. by mixing EtOAc 330 mL, ephedrine 10, tannic acid 20 g in 230 mL EtOAc and hexane 800 mL. The above tannate was quite pure and contained the base 30.44, and tannic acid 64.30%.

L22 ANSWER 12 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:71811 CAPLUS

DOCUMENT NUMBER: 136:123659

TITLE: A process for the manufacture of pharmaceutical grade tannic acid **salts**

INVENTOR(S): Khamar, Bakulesh Mafatlal; Srinivasan, Chidambaram Venkateswaran; Mitra, Jayati

PATENT ASSIGNEE(S): Cadila Pharmaceuticals Limited, India  
 SOURCE: PCT Int. Appl., 9 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005746	A2	20020124	WO 2001-IB1252	20010713
WO 2002005746	A3	20020502		

W: CA, MX, US

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, TR

PRIORITY APPLN. INFO.: IN 2000-MU662 A 20000714

AB Antihistamines are available in the form of free bases as well as **salts** i.e. hydrochlorides, **maleates**, tannates, etc. Frequently, it is necessary to utilize antihistamines in the form of tannate **salts** because such **salts** are generally quite stable and may be administered without any side effects. Tannic acid, which is available com., usually contains about 5% water, has a mol. wt. of about 1700 and is typically produced from Turkish or Chinese nut-gall. Antihistamine tannic acid **salts** presently manufd. com., are relatively impure. Such tannates are prepd. by the reaction of antihistamine base with tannic acid by using a volatile solvent, isopropanol (IPA). The yield is only fair (around 70%) and decompn. products e.g. 2-5% along with a significant amt., IPA (6-10%) remains with the product, which cannot be removed. According to present invention, for specific types of tannates, IPA is removed by adding water, while stirring and dispersing the wet cake of tannate. It is then filtered and the tannate residue is dried to obtain pharmaceutical grade tannate. Thus, chlorpheniramine tannate was prepd. by mixing IPA 850 mL, chlorpheniramine base 43.3, tannic acid 40.7 gms in 450 mL IPA, hexane 100 and water 1000 mL. The above tannate was quite pure and contained the base 41.65, and tannic acid 54.20%.

L22 ANSWER 13 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1990:520800 CAPLUS

DOCUMENT NUMBER: 113:120800

TITLE: Skin penetration enhancers for **salts** of amine-functional drugs

INVENTOR(S): Manring, Gary Lee; Smith, Ronald Lee

PATENT ASSIGNEE(S): Procter and Gamble Co., USA

SOURCE: Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 351897	A2	19900124	EP 1989-201447	19890606
EP 351897	A3	19900321		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8936511	A1	19891221	AU 1989-36511	19890616
DK 8902983	A	19900202	DK 1989-2983	19890616
ZA 8904588	A	19900328	ZA 1989-4588	19890616
JP 02209815	A2	19900821	JP 1989-155565	19890617

PRIORITY APPLN. INFO.: US 1988-208197 19880617

AB The transdermal penetration of amine-functional drug addn. **salts**

(other than opioid analgesics) is enhanced by C7-22 fatty acids (m.p. <50.degree.) used together with C3-4 alkanediols. The in vitro transdermal penetration of pseudoephedrine-HCl through the human skin was enhanced by a 5:95 mixt. of 1,2-propanediol and oleic acid.

L22 ANSWER 14 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1988:535073 CAPLUS  
DOCUMENT NUMBER: 109:135073  
TITLE: Analysis of some dosage forms containing pyridine derivatives using a cyclodextrin bonded stationary phase in HPLC  
AUTHOR(S): El Gezawi, S.; Omar, N.; El Rabbat, N.; Perrin, J. H.  
CORPORATE SOURCE: Dep. Pharm., Univ. Assiut, Assiut, Egypt  
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (1988), 6(4), 393-8  
CODEN: JPBADA; ISSN: 0731-7085  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The HPLC of some pyridine derivs. using a silica column to which .beta.-cyclodextrin has been bonded, was investigated. In spite of the low affinity consts. of the drugs for cyclodextrin (102 M-1) good sepns. were achieved using a mobile phase of MeOH and pH 7.0 phosphate. Pheniramine maleate, pyrilamine maleate, and phenylpropanolamine were detd. in dosage forms. Extns. and chromatog. are quick and simple.

L22 ANSWER 15 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:546946 CAPLUS  
DOCUMENT NUMBER: 122:274115  
TITLE: Compositions containing an amino acid salt of a propionic acid nonsteroidal antiinflammatory agent and at least one of a decongestant, an expectorant, an antihistamine, and an antitussive  
INVENTOR(S): Mitra, Sekhar  
PATENT ASSIGNEE(S): Procter and Gamble Co., USA  
SOURCE: PCT Int. Appl., 17 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9507103	A1	19950316	WO 1994-US9581	19940824
W: AU, BR, CA, CN, JP, PL, RU				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2170488	AA	19950316	CA 1994-2170488	19940824
AU 9476040	A1	19950327	AU 1994-76040	19940824
EP 719156	A1	19960703	EP 1994-926020	19940824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1130354	A	19960904	CN 1994-193312	19940824
BR 9407414	A	19961112	BR 1994-7414	19940824
JP 09502201	T2	19970304	JP 1994-508695	19940824
PRIORITY APPLN. INFO.:			US 1993-116927	19930907
			WO 1994-US9581	19940824

AB A method for providing improved treatment, management, or mitigation of cold, coldlike, and/or flu symptoms comprises administering a safe and effective amt. of a compn. comprising certain amino acid salts of propionic acid nonsteroidal antiinflammatory agents along with .gtoreq.1 of a decongestant, expectorant, antihistamine, and antitussive. Thus, a hard gelatin capsule contained naproxen lysinate 200,

pseudoephedrine-HCl 30, astemizole 5, and glyceryl guaiacolate 100 mg.

L22 ANSWER 16 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1965:65827 CAPLUS

DOCUMENT NUMBER: 62:65827

ORIGINAL REFERENCE NO.: 62:11633d-e

TITLE: Spectrophotometric study of **phenylephrine** hydrochloride

AUTHOR(S): Volta, Aida Herrera

SOURCE: Rev. Fac. Farm. Univ. Central Venezuela (1964), 5(12), 96-104

DOCUMENT TYPE: Journal

LANGUAGE: Spanish

AB A soln. of 4 mg. **phenylephrine** in 100 ml. H<sub>2</sub>O was prepd. and the absorbance at 273 m. $\mu$ . detd. Formulas were applied for the detn. of this compd. alone and in admixt. with **Pyrilamine maleate** and Tenyldiamine-HCl. This method was proposed to replace the official bromometric detn.

L22 ANSWER 17 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1964:17058 CAPLUS

DOCUMENT NUMBER: 60:17058

ORIGINAL REFERENCE NO.: 60:3026d-e

TITLE: Alkyl acid phosphate **salts**

PATENT ASSIGNEE(S): Leo K. Roehen

SOURCE: 2 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3107262		19631015	US	19620125

AB Acid addn. **salts** of mono- and distearyl H phosphates and stoichiometric of nitrogenous bases such as: dl- and l-amphetamine, chlorpheniramine, methamphetamine, phenylpropanolamine, **pyrilamine**, pheniramine, methapyrilene, l-ephedrine, quinidine, codeine, and **phenylephrine** were prepd. These **salts** are non-irritating and are characterized by the absence of side effects and increased duration of activity for which the bases are employed (antihistamine, analeptic, ataractic, anorectic, vasoconstrictor, narcotic, etc.).

L22 ANSWER 18 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1967:467586 CAPLUS

DOCUMENT NUMBER: 67:67586

TITLE: Antitussive-enzyme preparations

PATENT ASSIGNEE(S): Rorer, William H., Inc.

SOURCE: Brit., 5 pp.

CODEN: BRXXAA

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1064581		19670405		

PRIORITY APPLN. INFO.: US 19640406

AB Oral compns. of an antitussive with a protease are claimed. Thus, the preferred dosage is d-methorphan-HBr 15, bromelain 40, l-**phenylephrine**-HCl 5, **pyrilamine maleate** 12.5,

and homatropine methylbromide 1.5 mg.

L22 ANSWER 19 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1967:476350 CAPLUS

DOCUMENT NUMBER: 67:76350

TITLE: Application of ion-pair extraction to partition chromatographic separation of pharmaceutical amines

AUTHOR(S): Doyle, Thomas D.; Levine, Joseph

CORPORATE SOURCE: Food and Drug Admin., U. S. Dep. of Health, Educ., and Welfare, Washington, DC, USA

SOURCE: Analytical Chemistry (1967), 39(11), 1282-7

CODEN: ANCHAM; ISSN: 0003-2700

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The application of ion-pair extn. of pharmaceutical amines from aq. acid solns. to the partition chromatographic sepn. of the amines is studied. The log of the distribution ratio is plotted against pH and the resulting diagrams can be used to select optimum conditions for the sepn. of the amine mixt. The approach is illustrated with the **pyrilamine maleate/codeine sulfate** mixt. Distribution diagrams are presented for aq. NO<sub>3</sub><sup>-</sup> stationary phases supported on acid-washed Celite 545. An aq. stationary phase of M NO<sub>3</sub><sup>-</sup>, buffered to pH 4.5, or an aq. soln. at pH 5.0 in the presence or absence of NO<sub>3</sub><sup>-</sup> are esp. useful. **Pyrilamine** is eluted quant. with Et<sub>2</sub>O, then codeine with CHCl<sub>3</sub>. The chromatographic behavior of 7 pharmaceutical amines with 6 acidic stationary phases is tabulated. The table can be used to det. suitable conditions for the selective elution of .gtoreq.1 of the amines from mixts. by CHCl<sub>3</sub> eluant.

L22 ANSWER 20 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1965:457421 CAPLUS

DOCUMENT NUMBER: 63:57421

ORIGINAL REFERENCE NO.: 63:10515d-g

TITLE: Preliminary investigation of the pharmacology of longitudinal muscle strips from human isolated jejunum

AUTHOR(S): Whitney, B.

CORPORATE SOURCE: King's Coll. Hosp. Med. School, London

SOURCE: J. Pharm. Pharmacol. (1965), 18(8), 465-73

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Physostigmine **sulfate** potentiated, and ( - )-hyoscine-HBr (I) inhibited the contractions of the human jejunal muscle strips induced by acetylcholine perchlorate (II). Hexamethonium **bromide** (III), which completely blocked the response of the muscle to dimethylphenylpiperazinium iodide (IV), had no effect on the response to II. The sympathomimetic amines, (+)-phenylephrine-HCl, ( - )-noradrenaline bitartrate, and (.+.)-isoprenaline **sulfate** (V) relaxed the muscle and prevented spontaneous activity in the muscle strips. Pronethalol-HCl abolished the inhibitory effect of (-)-noradrenaline bitartrate and V, the response to the latter was abolished at a lower concn. and hydergine abolished the inhibitory effect of ( + )-**phenylephrine** on the contractile response to II and slightly reduced the response to V. Eserine potentiated the contractile response to IV, and III reversibly inhibited it. I blocked or even reversed the response to IV. III abolished the relaxation caused by IV in the presence of I, however, the contractile response to 5-hydroxytryptamine creatinine **sulfate** (VI) was not affected by I, mepyramine **maleate**, or by III. Methysergide hydrogen **maleate** which had no effect on the response of the muscle to II completely inhibited the response to VI. III and I had no effect while mepyramine **maleate** completely inhibited the contractile response to histamine acid phosphate. These results demonstrated (1) the presence of both .alpha.- and

.beta.-receptors in the human jejunum, (2) the presence of both cholinergic (dominant) and adrenergic nervous tissue (demonstrated by the responses to IV), (3) that histamine acid phosphate and VI exert a direct effect on the longitudinal muscle, and (4) that II acts on the muscarine site.

L22 ANSWER 21 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1987:483926 CAPLUS  
DOCUMENT NUMBER: 107:83926  
TITLE: Magnesium aluminum silicate-wax as medicament adsorbates  
INVENTOR(S): Mozda, Ronald F.  
PATENT ASSIGNEE(S): Warner-Lambert Co., USA  
SOURCE: Eur. Pat. Appl., 29 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 219458	A2	19870422	EP 1986-810428	19860929
EP 219458	A3	19880120		
EP 219458	B1	19900523		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
US 4753800	A	19880628	US 1985-784280	19851004
AU 8663456	A1	19870409	AU 1986-63456	19861001
AU 565750	B2	19870924		
JP 62116507	A2	19870528	JP 1986-234741	19861003
JP 02020604	B4	19900510		
CA 1276885	A1	19901127	CA 1986-519723	19861003
PRIORITY APPLN. INFO.:			US 1985-784280	19851004

AB Medications are dissolved or dispersed in molten edible wax, and sorbed into Mg Al silicate. This process masks the taste of the medication more effectively than simple adsorption into Mg Al silicate. Guaifenesin 160 g was added to molten carnauba wax 310 g, and Mg Al silicate 530 g was mixed in. After cooling, the solid was milled to give free flowing particles of .apprx.100 .mu.m. This compn. had a good taste, whereas 16% guaifenesin in carnauba wax or in Mg Al silicate both had a bitter taste.  
**Pyrilamine maleate** adsorbate(25 mg drug/tablet) 250.0 mg was mixed with cellulose 34.0, lactose 136.8, cellulose gum 2.0, fumed silica 0.7, stearic acid 0.5, and Mg stearate 1.0 mg/tablet.

L22 ANSWER 22 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:31287 CAPLUS  
DOCUMENT NUMBER: 134:105670  
TITLE: Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use  
INVENTOR(S): Yu, Ruey J.; Van Scott, Eugene J.  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001932	A2	20010111	WO 2000-US16301	20000628
WO 2001001932	A3	20010517		



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6335023 B1 20020101 US 2000-487228 20000119  
 BR 2000011640 A 20020514 BR 2000-11640 20000628  
 EP 1227820 A2 20020807 EP 2000-950220 20000628

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003503436 T2 20030128 JP 2001-507430 20000628  
 US 2002028227 A1 20020307 US 2001-987023 20011113

PRIORITY APPLN. INFO.: US 1999-141264P P 19990630  
 US 2000-487228 A 20000119  
 WO 2000-US16301 W 20000628

OTHER SOURCE(S): MARPAT 134:105670

AB Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatol. disorders, including those assocd. with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepd. by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in treatment of dry skin is reported.

L22 ANSWER 23 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:812193 CAPLUS  
 DOCUMENT NUMBER: 128:80034  
 TITLE: A nasal spray containing an intranasal steroid and an antihistamine  
 INVENTOR(S): Koochaki, Patricia Elaine  
 PATENT ASSIGNEE(S): Procter & Gamble Company, USA  
 SOURCE: PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9746243	A1	19971211	WO 1997-US9518	19970603
W: AU, BR, CA, CN, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9731537	A1	19980105	AU 1997-31537	19970603
CN 1222852	A	19990714	CN 1997-195225	19970603
BR 9709650	A	19990810	BR 1997-9650	19970603
JP 11511758	T2	19991012	JP 1997-500771	19970603
EP 954318	A1	19991110	EP 1997-926878	19970603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRIORITY APPLN. INFO.:		US 1996-657506		19960604
		WO 1997-US9518		19970603

AB Pharmaceutical compns. for nasal administration comprise (a) a safe and effective amt. of a glucocorticoid selected from the group consisting of

beclomethasone, flunisolide, fluticasone, memetasone, budesonide, pharmaceutically acceptable **salts** thereof and mixts. thereof; (b) a safe and effective amt. of a fast acting antihistamine selected from the group consisting of acrivastine, carbinoxamine, diphenhydramine, chlorpheniramine, brompheniramine, dexchloropheniramine, doxylamine, clemastine, promethazine, trimeprazine, methdilazine, hydroxyzine, **pyrilamine**, rocastine, tripelennamine, meclizine, triprolidine, azatadine, cyproheptadine, phenindamine, pharmaceutically acceptable **salts** thereof and mixts. thereof; and (c) an aq., intranasal carrier wherein the compn. is free of capsaicin and, preferably, free of powders or granules. The present invention also relates to a method for the treatment of symptoms assocd. with seasonal or perennial allergic rhinitis comprising the administration of a safe and effective amt. of the intranasal pharmaceutical compns. of the present invention. A nasal spray contained beclomethasone dipropionate monohydrate 0.042, chlorpheniramine 0.500, Avicel RC-591 1.200, dextrose 5.100, Polysorbate 80 0.050, benzalkonium **chloride** 0.020, phenylethyl alc. 0.025, and water q.s. 100%.

ACCESSION NUMBER: 1982:538350 CAPLUS  
DOCUMENT NUMBER: 97:138350  
TITLE: Pharmacological comparison of human isolated digital  
arteries and metacarpal veins  
AUTHOR(S): Stevens, M. J.; Moulds, R. F. W.  
CORPORATE SOURCE: Dep. Med., Univ. Melbourne, Melbourne, Australia  
SOURCE: Clinical and Experimental Pharmacology and Physiology  
(1982), 9(2), 129-38  
CODEN: CEXPB9; ISSN: 0305-1870

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The responses of human digital arteries and metacarpal veins obtained postmortem to various pharmacol. agents were tested. The pD<sub>2</sub> values for KCl and BaCl<sub>2</sub> were found to be greater in arteries than in veins. There was no difference between the arteries and veins in the pA<sub>2</sub> values for phentolamine mesylate [65-28-1] as an antagonist of either L-arterenol bitartrate (noradrenaline) [51-40-1] or **phenylephrine** [59-42-7]. The pD<sub>2</sub> values for noradrenaline however, were significantly higher in the veins than in the arteries, whereas pD<sub>2</sub> values for **phenylephrine** in the 2 tissues were not significantly different. This raises the possibility of there being differences in the populations of  $\alpha$ -adrenoceptors in the 2 tissues. Differences were found between arteries and veins in the contractile and relaxant responses to histamine [51-45-6] and in the antagonism of the responses to histamine by cimetidine [51481-61-9] and mepyramine **maleate** thereby suggesting differences in the populations of H<sub>1</sub>- and H<sub>2</sub>-receptors in these tissues. No differences were found in the responses of arteries and veins to serotonin [50-67-9] or in the antagonism of the response to this agonist by phentolamine. isoprenaline [7683-59-2] Produced relaxant responses in veins (in which tone was induced with 30 mmol/L KCl) but not in arteries. dopamine [51-61-6] Produced very weak relaxant responses in preps. in which tone was induced using 30 mmol/L KCl. The mean E<sub>max</sub> value for this response was significantly greater in veins than in arteries. Slight relaxant responses to acetylcholine [51-84-3] were seen in veins and arteries precontracted with 30 mmol/L KCl. The mean E<sub>max</sub> value was significantly greater in veins than in arteries. Thus, human digital arteries and metacarpal veins have differing pharmacol. receptor populations and probably also differ in their non-receptor mediated contractile mechanisms.

L22 ANSWER 31 OF 76 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1976:437309 CAPLUS

DOCUMENT NUMBER: 85:37309

TITLE: Analysis of pharmaceuticals associated in various formulations by high-speed liquid chromatography

AUTHOR(S): Caude, M.; Le Xuan Phan

CORPORATE SOURCE: Lab. Chim. Anal., Ec. Super. Phys. Chim. Paris, Paris, Fr.

SOURCE: Chromatographia (1976), 9(1), 20-9

CODEN: CHRGB7; ISSN: 0009-5893


DOCUMENT TYPE: Journal

LANGUAGE: French

AB Eleven sepns. of pharmaceuticals encountered in various formulations were made by high speed adsorption liq. chromatog. on spherosil-type silica, nominal diameter 5  $\mu$ m: noscapine [128-62-1]-promethazine [60-87-7]; mepyramine **maleate** [59-33-6]-dextromethorphan-HBr [125-69-9]; Me [99-76-3] and Pr p-hydroxybenzoate [94-13-3]; amidopyrine [58-15-1] and butazolidine [50-33-9]; methaqualone [72-44-6] and paracetamol [103-90-2]; paraoxypropione [70-70-2], phenobarbital [50-06-6] and methylthiouracil [56-04-2]; benzocaine-HCl [23239-88-5], procaine-HCl [51-05-8], and tetracaine-HCl [136-47-0]; phenobarbital, papaverine-HCl [61-25-6] and theophylline [58-55-9]; phenobarbital, caffeine [58-08-2], amidopyrine, and nicotinamide [98-92-0]; biclotymol [15686-33-6], neosynephrine-HCl [61-76-7], paracetamol, and glycerol guaiacolate; lignocaine [137-58-6], hydrocortisone **acetate** [50-03-3], and butazolidine. Except for the last all these sepns. are achieved by the isocratic mode with short columns (15 cm max.) and pressure <50 bars. Anal. time is always <20 min.

RN 614-03-9 REGISTRY  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (.alpha.S)-  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (S)-  
 CN Benzyl alcohol, m-hydroxy-.alpha.-[(methylamino)methyl]-, (+)- (8CI)  
 OTHER NAMES:  
 CN (+)-m-Synephrine  
 CN (+)-Phenylephrine  
 CN d-Phenylephrine  
 CN L-(+)-Phenylephrine  
 CN L-Phenylephrine  
 FS STEREOSEARCH  
 MF C9 H13 N O2  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, BEILSTEIN\*, BIOBUSINESS, BIOSIS, CA,  
 CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHM, GMELIN\*, TOXCENTER  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

127 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 127 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 37 OF 40 REGISTRY COPYRIGHT 2003 ACS  
 RN 154-86-9 REGISTRY  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride,  
 (.+-.)-  
 CN Benzyl alcohol, m-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride,  
 (.+-.)- (8CI)  
 OTHER NAMES:  
 CN (.+-.)-Phenylephrine hydrochloride  
 CN 1-(3-Hydroxyphenyl)-2-methylaminoethanol hydrochloride  
 CN DL-Phenylephrine hydrochloride  
 DR 20368-45-0  
 MF C9 H13 N O2 . Cl H  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,  
 CSCHEM, IFICDB, IFIPAT, IFIUDB, RTECS\*, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (1477-63-0)



● HCl


21 REFERENCES IN FILE CA (1962 TO DATE)  
 21 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 38 OF 40 REGISTRY COPYRIGHT 2003 ACS  
 RN 61-95-0 REGISTRY  
 CN Benzenemethanol, .alpha.-(aminomethyl)-3-hydroxy-, (R)-,  
 (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, .alpha.-(aminomethyl)-3-hydroxy-, (R)-,  
 [R-(R\*,R\*)]-2,3-dihydroxybutanedioate (1:1) (salt)  
 CN Benzyl alcohol, .alpha.-(aminomethyl)-m-hydroxy-, tartrate (1:1), (-)-  
 (8CI)  
 OTHER NAMES:  
 CN 1-Norphenylephrine bitartrate  
 FS STEREOSEARCH  
 MF C8 H11 N O2 . C4 H6 O6  
 LC STN Files: CA, CAOLD, CAPLUS

CM 1

CRN 1420-80-0  
 CMF C8 H11 N O2

Absolute stereochemistry.




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1962 TO DATE)

3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 39 OF 40 REGISTRY COPYRIGHT 2003 ACS

RN 61-76-7 REGISTRY

CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride, (.alpha.R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride, (R)-

CN Benzyl alcohol, m-hydroxy-.alpha.-[(methylamino)methyl]-, hydrochloride, (-)- (8CI)

OTHER NAMES:

CN (-)-.alpha.-Hydroxy-.beta.-(methylamino)ethyl-.alpha.-(3-hydroxybenzene)hydrochloride

CN **(-)-Phenylephrine hydrochloride**

CN **(R)-Phenylephrine hydrochloride**

CN Adrianol

CN Ak-Dilate

CN Ak-Nefrin

CN Alcon Efrin

CN Almefrin

CN Decadron

CN Isophrin

CN Isophrin hydrochloride

CN 1-.alpha.-Hydroxy-.beta.-methylamino-3-hydroxy-1-ethylbenzene hydrochloride

CN 1-1-(m-Hydroxyphenyl)-2-methylaminoethanol hydrochloride


CN 1-m-Hydroxy-.alpha.-[(methylamino)methyl]benzyl alcohol hydrochloride

CN **1-Phenylephrine hydrochloride**

CN **Levophenylephrine hydrochloride**

CN Lexatol  
 CN M-Sympatol  
 CN Meta-Sympatol  
 CN Meta-Synephrine hydrochloride  
 CN Metaoxedrine chloride  
 CN Metaoxedrine hydrochloride  
 CN Mydfrin  
 CN Neo-Synephrine hydrochloride  
 CN Neo-Synesis 1  
 CN Neophryn  
 CN Nostril  
 CN Oftalfrine  
 CN **Phenylephrine hydrochloride**  
 CN Prefrin  
 CN Pyracort D  
 CN R-(-)-m-Synephrine hydrochloride  
 CN Sucraphen  
 CN Synasal  
 FS STEREOSEARCH  
 DR 644-22-4, 827-62-3, 50741-76-9  
 MF C9 H13 N O2 . Cl H  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,  
 CSCHEM, DIOGENES, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK\*,  
 MSDS-OHS, NIOSHTIC, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (59-42-7)

Absolute stereochemistry.



● HCl

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


851 REFERENCES IN FILE CA (1962 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 851 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 40 OF 40 REGISTRY COPYRIGHT 2003 ACS  
 RN 59-42-7 REGISTRY  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (.alpha.R)-  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (R)-



CN Benzyl alcohol, m-hydroxy-.alpha.-[(methylamino)methyl]-, (-)- (8CI)  
 OTHER NAMES:  
 CN (-)-m-Hydroxy-.alpha.- (methylaminomethyl)benzyl alcohol  
 CN (-)-m-Synephrine  
 CN **(-)-Phenylephrine**  
 CN **(R)-(-)-Phenylephrine**  
 CN **(R)-Phenylephrine**  
 CN 1-m-Hydroxy-.alpha.-[(methylamino)methyl]benzyl alcohol  
 CN L-Phenylephedrine  
 CN **1-Phenylephrine**  
 CN m-Methylaminoethanolphenol  
 CN Mesaton  
 CN Mesatone  
 CN Metaoxedrin  
 CN Metaoxedrine  
 CN Metasympatol  
 CN Metasynephrine  
 CN Mezaton  
 CN Neo-Synephrine  
 CN **Phenylephrine**  
 CN R(-)-Mezaton  
 CN Visadron  
 FS STEREOSEARCH  
 MF C9 H13 N O2  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
 BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS,  
 CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN\*, HSDB\*,  
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, NAPRALERT, NIOSHTIC, PHAR, PROMT,  
 RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


5624 REFERENCES IN FILE CA (1962 TO DATE)  
 37 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 5625 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 15 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 5 OF 40 REGISTRY COPYRIGHT 2003 ACS  
 RN 60374-14-3 REGISTRY  
 CN Octadecanoic acid, compd. with (R)-3-hydroxy-.alpha.-  
 [(methylamino)methyl]benzenemethanol (1:1) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (R)-,  
 octadecanoate (salt) (9CI)  
 OTHER NAMES:  
 CN **Phenylephrine stearate**  
 FS STEREOSEARCH  
 MF C18 H36 O2 . C9 H13 N O2  
 LC STN Files: CA, CAPLUS

CM 1

CRN 59-42-7  
 CMF C9 H13 N O2

Absolute stereochemistry.



CM 2

CRN 57-11-4  
 CMF C18 H36 O2

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>16</sub>-Me

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L1 ANSWER 6 OF 40 REGISTRY COPYRIGHT 2003 AC

RN 33662-63-4 REGISTRY  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (-)-,  
 (2R,3R)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (-)-,  
 [R-(R\*,R\*)]-2,3-dihydroxybutanedioate (2:1) (salt)  
 CN **Tartaric acid, phenylephrine salt (6CI)**  
 FS STEREOSEARCH  
 MF C9 H13 N O2 . 1/2 C4 H6 O6  
 LC STN Files: CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB, TOXCENTER

CM 1

CRN 87-69-4  
 CMF C4 H6 O6


Absolute stereochemistry.



CM 2


CRN 59-42-7  
 CMF C9 H13 N O2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 1 REFERENCES IN

RN 1477-63-0 REGISTRY  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Benzenemethanol, 3-hydroxy-.alpha.-[(methylamino)methyl]-, (.+-.)-  
 CN Benzyl alcohol, m-hydroxy-.alpha.-[(methylamino)methyl]-, (.+-.)- (8CI)  
 OTHER NAMES:  
 CN (.+-.)-1-(3-Hydroxyphenyl)-1-hydroxy-2-(methylamino)ethane  
 CN (.+-.)-Neosynephrine  
 CN **(.+-.)-Phenylephrine**  
 CN 1-(3-Hydroxyphenyl)-2-(N-methylamino)ethanol  
 CN 1-(3-Hydroxyphenyl)-2-methylaminoethanol  
 CN 3-Hydroxy-.alpha.-[(methylamino)methyl]benzenemethanol  
 CN dl-Mesatone  
 CN **dl-Phenylephrine**  
 CN m-Hydroxy-.alpha.-[(methylamino)methyl]benzyl alcohol  
 CN m-Hydroxyphenylmethylaminoethanol  
 FS 3D CONCORD  
 DR 532-38-7.  
 MF C9 H13 N O2  
 CI COM  
 LC STN Files: BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMLIST, EMBASE, GMELIN\*, IPA, RTECS\*, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)



2 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 91-84-9 REGISTRY

CN 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]- (7CI, 8CI)

OTHER NAMES:

CN 2-[(2-Dimethylaminoethyl)(p-methoxybenzyl)amino]pyridine

CN Afko-Hist

CN Anhistabs

CN Anhistol

CN Antalergan

CN Antallergan

CN Anthisan

CN Copsamine

CN Coradon

CN Dipane

CN Dorantamin

CN Harvamine

CN Histacap

CN Histasan

CN Isamin

CN Kriptin

CN Maranhist

CN Mepyramine

CN Mepyren

CN N-p-Methoxybenzyl-N',N'-dimethyl-N-.alpha.-pyridylethylenediamine

CN Neo-Bridal

CN Neoantergan

CN Nyscaps

CN Pyra

CN Pyranisamine

CN **Pyrilamine**

CN RP 2786

CN Statomin

CN Wait's green mountain antihistamine

FS 3D CONCORD

DR 102206-59-7

MF C17 H23 N3 O


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUIDB, IPA, MEDLINE, MRCK\*, NIOSHTIC, PROMT, RTECS\*, SPECINFO, TOXCENTER, USAN, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

562 REFERENCES IN FILE CA (1962 TO DATE)

12 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

563 REFERENCES IN FILE CAPLUS (1962 TO DATE)

2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 59-33-6 REGISTRY

CN 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N',N'-dimethyl-N-2-pyridinyl-, (Z)-2-butenedioate (1:1)

CN Pyridine, 2-[[2-(dimethylamino)ethyl](p-methoxybenzyl)amino]-, maleate (1:1) (8CI)

OTHER NAMES:

CN 2-[(2-Dimethylaminoethyl)(p-methoxybenzyl)amino]-pyridine maleate

CN 2-[[2-(Dimethylamino)ethyl](p-methoxybenzyl)amino]pyridine Bimaleate

CN AH

CN Anisopyradamine

CN Antamine

CN Anthisan maleate

CN Antihist

CN Antisan

CN Diaminide maleate

CN Enrumay

CN Histalet Forte

CN Histalon

CN Histan

CN Histapyran

CN Histatex

CN Histavet P

CN Mepyramine hydrogen maleinate

CN Mepyramine maleate

CN Midol

CN Minihist

CN N-p-Methoxybenzyl-N',N'-dimethyl-N-.alpha.-pyridylethylenediamine maleate

CN Neo-Antergan maleate

CN Neoantergan maleate

CN Paramal

CN Paraminyl

CN Paraminyl maleate

CN Parmal

CN Prefrin A

CN PV Tussin Syrup

CN Pymafed

CN Pyra Maleate

CN Pyramal

CN Pyranilamine maleate

CN Pyraninyl

CN Pyranisamine maleate

CN **Pyrilamine maleate**

CN Renstamin

CN Stamina

CN Stangen

CN Stangen maleate

CN Statomin maleate

CN Thylogen

CN Thylogen maleate

FS STEREOSEARCH

DR 5572-06-5

MF C17 H23 N3 O . C4 H4 O4

CI COM


LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,

CSCHEM, DIOGENES, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*,  
MSDS-OHS, NIOSHTIC, PROMT, RTECS\*, TOXCENTER, USAN, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CM 1


CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



CM 2

CRN 91-84-9  
CMF C17 H23 N3 O



976 REFERENCES IN FILE CA (1962 TO DATE)  
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
976 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d his

(FILE 'HOME' ENTERED AT 17:03:14 ON 04 FEB 2003)

FILE 'REGISTRY' ENTERED AT 17:03:18 ON 04 FEB 2003

L1 40 S PHENYLEPHRINE  
L2 14 S PYRILAMINE  
L3 37 S TANNIC ACID OR TANNATE  
L4 7 S MAGNESIUM ALUMINUM SILICATE


RN 53570-13-1 REGISTRY  
 CN Aluminum magnesium oxide silicate (Al<sub>6</sub>Mg<sub>3</sub>O<sub>8</sub>(SiO<sub>4</sub>)<sub>2</sub>) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Aluminosilicic acid (H<sub>3</sub>Al<sub>3</sub>SiO<sub>8</sub>), magnesium salt (2:3)  
 CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), aluminum complex  
 OTHER NAMES:  
 CN **Magnesium aluminum silicate (Mg<sub>3</sub>Al<sub>6</sub>Si<sub>2</sub>O<sub>16</sub>)**  
 MF Al . Mg . O<sub>4</sub> Si . O  
 AF Al<sub>6</sub> Mg<sub>3</sub> O<sub>16</sub> Si<sub>2</sub>  
 CI TIS  
 LC STN Files: CA, CAPLUS

Component	Ratio	Component Registry Number
=====	=====	=====
O	8	17778-80-2
O <sub>4</sub> Si	2	17181-37-2
Mg	3	7439-95-4
Al	6	7429-90-5

1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L4 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 12511-31-8 REGISTRY  
 CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), aluminum magnesium salt (2:2:1) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Aluminosilicic acid (HAlSiO<sub>4</sub>), magnesium salt (8CI)  
 CN Magnesium aluminosilicate (MgAl<sub>2</sub>Si<sub>2</sub>O<sub>8</sub>) (6CI, 7CI)  
 OTHER NAMES:  
 CN Aluminum magnesium silicate  
 CN Angast  
 CN Magnesium aluminate metasilicate  
 CN Magnesium aluminosilicate (Mg(AlSiO<sub>4</sub>)<sub>2</sub>)  
 CN **Magnesium aluminum silicate (MgAl<sub>2</sub>(SiO<sub>4</sub>)<sub>2</sub>)**  
 CN **Magnesium aluminum silicate (MgAl<sub>2</sub>Si<sub>2</sub>O<sub>8</sub>)**  
 CN Neusilin  
 CN Neusilin FH 1  
 CN Neusilin FH 2  
 CN Neusilin FL2  
 CN Neusilin UFL  
 CN Neusilin UFL2  
 CN Neusilin US2  
 DR 24716-65-2, 50958-44-6, 37303-22-3, 107497-93-8  
 MF Al . H<sub>4</sub> O<sub>4</sub> Si . 1/2 Mg  
 CI COM  
 LC STN Files: BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, GMELIN\*, IFICDB, IFIPAT, IFIUDB, MRCK\*, PROMT, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 CRN (10193-36-9)





Al

1/2 Mg

164 REFERENCES IN FILE CA (1962 TO DATE)  
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 166 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L4 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 12252-50-5 REGISTRY  
 CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), aluminum magnesium salt (3:2:3) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Aluminosilicic acid (H<sub>6</sub>Al<sub>2</sub>Si<sub>3</sub>O<sub>12</sub>), magnesium salt (1:3) (8CI)  
 CN Magnesium aluminosilicate (Mg<sub>3</sub>Al<sub>2</sub>Si<sub>3</sub>O<sub>12</sub>) (7CI)

OTHER NAMES:

CN Aluminum magnesium silicate (Al<sub>2</sub>Mg<sub>3</sub>(SiO<sub>4</sub>)<sub>3</sub>)  
 CN Aluminum magnesium silicate (Al<sub>2</sub>Mg<sub>3</sub>Si<sub>3</sub>O<sub>12</sub>)  
 CN **Magnesium aluminum silicate (Mg<sub>3</sub>Al<sub>2</sub>Si<sub>3</sub>O<sub>12</sub>)**  
 DR 69466-19-9, 314070-11-6  
 MF Al . 3/2 H<sub>4</sub> O<sub>4</sub> Si . 3/2 Mg  
 LC STN Files: CA, CAOLD, CAPLUS, GMELIN\*, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (10193-36-9)



2/3 Al

Mg

87 REFERENCES IN FILE CA (1962 TO DATE)  
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 87 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 12040-43-6 REGISTRY  
 CN Silicic acid, aluminum magnesium sodium salt (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Aluminosilicic acid, magnesium sodium salt  
 OTHER NAMES:  
 CN Aluminum magnesium sodium silicate  
 CN Hydrex R  
 CN Hysnap  
 CN Magnesium sodium aluminosilicate  
 CN Simagel  
 CN **Sodium magnesium aluminum silicate**  
 DR 53802-22-5, 57679-45-5  
 MF Unspecified  
 CI MAN  
 LC STN Files: BIOTECHNO, CA, CAPLUS, CHEMCATS, CHEMLIST, CIN, EMBASE,  
 IFICDB, IFIPAT, IFIUDB, PROMT, TOXCENTER, USPATFULL  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 24 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 24 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L4 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 12026-11-8 REGISTRY  
 CN Aluminum magnesium oxide silicate (Al<sub>2</sub>MgO<sub>2</sub>(SiO<sub>4</sub>)) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Aluminosilicic acid (H<sub>2</sub>Al<sub>2</sub>SiO<sub>6</sub>), magnesium salt (1:1)  
 CN Magnesium aluminosilicate (MgAl<sub>2</sub>SiO<sub>6</sub>) (7CI)  
 CN Silicic acid (H<sub>4</sub>SiO<sub>4</sub>), aluminum complex  
 OTHER NAMES:  
 CN Aluminum magnesium silicate (Al<sub>2</sub>MgSiO<sub>6</sub>)  
 CN Aluminum magnesium silicon oxide (Al<sub>2</sub>MgSiO<sub>6</sub>)  
 CN **Magnesium aluminum silicate (MgAl<sub>2</sub>SiO<sub>6</sub>)**  
 CN Tomix AD 300  
 DR 1344-26-9  
 MF Al . Mg . O<sub>4</sub> Si . O  
 AF Al<sub>2</sub> Mg O<sub>6</sub> Si  
 CI COM, TIS  
 LC STN Files: CA, CAOLD, CAPLUS, USPATFULL

Component	Ratio	Component Registry Number
=====	=====	=====
O	2	17778-80-2
O <sub>4</sub> Si	1	17181-37-2
Mg	1	7439-95-4
Al	2	7429-90-5

25 REFERENCES IN FILE CA (1962 TO DATE)  
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 25 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 4 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 11089-88-6 REGISTRY  
 CN Aluminum magnesium oxide silicate (Al<sub>2</sub>MgO(Si<sub>2</sub>O<sub>5</sub>)<sub>3</sub>) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Aluminate(1-), octaoxotrisilicate-, magnesium (2:1)  
 CN Aluminosilicic acid (HAlSi<sub>3</sub>O<sub>8</sub>), magnesium salt (8CI)

CN Magnesium aluminosilicate (MgAl<sub>2</sub>Si<sub>6</sub>O<sub>16</sub>) (6CI)  
 OTHER NAMES:  
 CN **Magnesium aluminum silicate (MgAl<sub>2</sub>Si<sub>6</sub>O<sub>16</sub>)**  
 MF Al . Mg . O<sub>5</sub> Si<sub>2</sub> . O  
 AF Al<sub>2</sub> Mg O<sub>16</sub> Si<sub>6</sub>  
 CI TIS  
 LC STN Files: CA, CAOLD, CAPLUS

Component	Ratio	Component Registry Number
=====	=====	=====
O <sub>5</sub> Si <sub>2</sub>	3	20328-07-8
O	1	17778-80-2
Mg	1	7439-95-4
Al	2	7429-90-5

3 REFERENCES IN FILE CA (1962 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)  
 1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2003 ACS  
 RN 1327-43-1 REGISTRY  
 CN Silicic acid, aluminum magnesium salt (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:

CN Aluminosilicic acid, magnesium salt (8CI)  
 OTHER NAMES:

CN Adakel  
 CN Aluminum magnesium oxide silicate  
 CN Aluminum magnesium silicate  
 CN Aluminum magnesium silicon oxide  
 CN Attagel 20  
 CN Biltcote  
 CN Magnabrite S  
 CN Magnabrite T  
 CN Magnesium aluminosilicate  
 CN **Magnesium aluminum silicate**  
 CN Magnesium silicate aluminate  
 CN Neutralon  
 CN Van Gel  
 CN Zeolex 94HP  
 DR 12768-32-0, 9000-67-3, 51668-34-9, 39390-03-9  
 MF Unspecified  
 CI COM, MAN

LC STN Files: ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,  
 CANCERLIT, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHM, DIOGENES,  
 EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, PIRA, PROMT,  
 RTECS\*, TOXCENTER, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 982 REFERENCES IN FILE CA (1962 TO DATE)  
 20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 986 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 17:03:14 ON 04 FEB 2003)

FILE 'REGISTRY' ENTERED AT 17:03:18 ON 04 FEB 2003

L1	40 S	PHENYLEPHRINE
L2	14 S	PYRILAMINE
L3	37 S	TANNIC ACID OR TANNATE
L4	7 S	MAGNESIUM ALUMINUM SILICATE

=> d 13 36-37

3 ANSWER 35 OF 37 REGISTRY COPYRIGHT 2003 ACS

RN 1401-55-4 REGISTRY \*

\* Use of this CAS Registry Number alone as a search term in other STN files may result in incomplete search results. For additional information, enter HELP RN\* at an online arrow prompt (=>).

CN Tannins (CA INDEX NAME)

OTHER NAMES:

CN AL

CN AL (tannin)

CN Brewtan

CN Catechins

CN F-Tannin

CN Floctan 1

CN Floctan 3

CN Fresh Shiraimatsu FS 500M

CN **Gallotannic acids**

CN Gallotannins

CN Hifix SL

CN Hifix SLA

CN MP-TR

CN Quertanil

CN Resorcinex Pecan Tannin 9901L

CN Sunlife TN

CN Tanal 1

CN Tanaphen P 500

CN Tanex RS 93

CN **Tannic Acid KT**

CN **Tannic Acid X**

CN **Tannic acids**

CN TW 75

CN Vitanyl B

CN Vitanyl IM

CN Weibull

DEF Gallic acid derivatives found in nutgalls, bark and other plant parts, especially oak bark.

DR 93615-37-3, 67167-65-1, 61790-06-5, 73891-88-0

MF Unspecified

CI COM, MAN, CTS

LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS\*, TOXCENTER, USAN, USPATFULL, VTB  
(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

100 REFERENCES IN FILE CA (1962 TO DATE)

100 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 36 OF 37 REGISTRY COPYRIGHT 2003 ACS

RN 1397-74-6 REGISTRY

CN **Acetyltannic acid (8CI, 9CI)** (CA INDEX NAME)

OTHER NAMES:

CN Acetannin

CN **Diacetyltannic acid**

CN Tannigen

CN Tannyl acetate

MF Unspecified

CI MAN

LC STN Files: CHEMLIST, MRCK\*, USAN

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

4  
L3 ANSWER 35 OF 37 REGISTRY COPYRIGHT 2003 ACS

RN 1401-55-4 REGISTRY \*

\* Use of this CAS Registry Number alone as a search term in other STN files may result in incomplete search results. For additional information, enter HELP RN\* at an online arrow prompt (=>).

CN Tannins (CA INDEX NAME)

OTHER NAMES:

CN AL

CN AL (tannin)

CN Brewtan

CN Catechins

CN F-Tannin

CN Floctan 1

CN Floctan 3

CN Fresh Shiraimatsu FS 500M

CN **Gallotannic acids**

CN Gallotannins

CN Hifix SL

CN Hifix SLA

CN MP-TR

CN Quertanil

CN Resorcinex Pecan Tannin 9901L

CN Sunlife TN

CN Tanal 1

CN Tanaphen P 500

CN Tanex RS 93

CN **Tannic Acid KT**

CN **Tannic Acid X**

CN **Tannic acids**

CN TW 75

CN Vitanyl B

CN Vitanyl IM

CN Weibull

DEF Gallic acid derivatives found in nutgalls, bark and other plant parts, especially oak bark.

DR 93615-37-3, 67167-65-1, 61790-06-5, 73891-88-0

MF Unspecified

CI COM, MAN, CTS

LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS\*, TOXCENTER, USAN, USPATFULL, VTB  
(\*File contains numerically searchable property data)

Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

100 REFERENCES IN FILE CA (1962 TO DATE)

100 REFERENCES IN FILE CAPLUS (1962 TO DATE)